98%
921
2 minutes
20
Background: It is important to establish a coronary heart disease (CHD) prediction model with high efficiency and precision for early diagnosis of CHD using clinical information. While existing deep learning-based CHD prediction models possess the limitations of large datasets and long training time, existing machine learning-based CHD prediction models have the limitations of low accuracy and robustness, which are unsuitable for clinical application. This study aimed to design a fast and high-precision intelligent model using clinical information to predict CHD.
Methods: Five public datasets, including 303, 293, 303, 200, and 123 patients with 55, 14, 14, 14, and 14 attributes, respectively, were used for model training and testing. After data preprocessing, the singular value decomposition method was utilized to extract features to build the CHD prediction model. Then, the CHD prediction model was established using the 5-fold cross-validation method with a multilayer perceptron approach.
Results: Results show that the established model performs better on the total dataset than the other models we built in this study. This machine learning-based CHD prediction model achieved an improved area under the curve (AUC of 99.10%, with 96.63% accuracy, 96.50% precision, 97.4% recall, and 97.0% -score on the total dataset.
Conclusions: This high precision and efficiency achieved by the proposed model on different datasets would be significant for the prediction of CHD for medical and clinical diagnosis purposes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951285 | PMC |
http://dx.doi.org/10.31083/RCM26204 | DOI Listing |
Medicine (Baltimore)
September 2025
Pediatric Laboratory, Hunan Provincial People's Hospital (The First Hospital Affiliated with Hunan Normal University) Laboratory Physician, Changsha, China.
This study explored the effects of Jiuwei Zhenxin (JWZX) granules on serum triggering receptor expressed on myeloid cells 1 (TREM1) levels and their role in regulating depression and anxiety in patients with coronary heart disease (CHD). A total of 100 CHD patients were enrolled from January 2020 to January 2023: 50 received JWZX granules and 50 underwent conventional treatment. Clinical data and psychological scores were collected.
View Article and Find Full Text PDFInt J Chron Obstruct Pulmon Dis
September 2025
Department of Cardiovascular Center, The First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People's Republic of China.
Objective: This study aimed to develop and validate a deep learning radiomics (DLR) nomogram for individualized CHD risk assessment in the COPD population.
Methods: This retrospective study included 543 COPD patients from two different centers. Comprehensive clinical and imaging data were collected for all participants.
Cureus
September 2025
Department of Paediatric Histopathology, Alder Hey Children's Hospital, Liverpool, GBR.
Congenital heart disease (CHD) is the most common congenital anomaly. While surgical and interventional advancements have improved survival, the management of associated complications and comorbidities remains complex and would benefit from a personalised approach that more accurately predicts individualised risks and prognoses. Recently, next-generation sequencing has uncovered diverse genetic factors, including epigenetic modifications, somatic mosaicism and regulatory non-coding variants.
View Article and Find Full Text PDFJ Mol Biol
September 2025
CHU Sainte-Justine Research Center, University of Montreal, Montreal, Quebec, Canada. Electronic address:
Chromodomain Helicase DNA-binding (CHD) proteins compose a family of chromatin remodelers that play crucial roles in DNA repair and gene expression regulation, neural stem cell differentiation and chromatin integrity. Genetic variants in CHD chromatin remodelers are associated with neurodevelopmental disorders with features like autism spectrum disorder and intellectual disability. Consequently, the determination of variant pathogenicity in clinical genetic tests for individuals bearing CHD variants is crucial.
View Article and Find Full Text PDFAm J Cardiol
September 2025
Seymour, Paul, and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, NY.
Women with cardiac disease have worse neonatal outcomes compared to women without cardiac disease; risk factors are not well-defined. We hypothesized that structural heart disease, as assessed by echocardiography, is a non-invasive metric for abnormal hemodynamics and an unfavorable maternal-fetal environment. We assessed the association between echocardiographic markers of structural heart disease in women with cardiac disease and a primary endpoint of adverse neonatal outcomes operationalized as neonates with small-for-gestational-age birth weight, preterm delivery, neonatal intensive care unit/transition care unit admission, or neonatal/fatal demise.
View Article and Find Full Text PDF